Frank J Warnders1, Stijn J H Waaijer2, Martin Pool2, Marjolijn N Lub-de Hooge3, Matthias Friedrich4, Anton G T Terwisscha van Scheltinga1, Petra Deegen4, Sabine K Stienen4, Peter C Pieslor5, H Kam Cheung5, Jos G W Kosterink6, Elisabeth G E de Vries7. 1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Amgen Research (Munich) GmbH, Munich, Germany. 5. Amgen, Thousand Oaks, California; and. 6. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Department of Pharmacy, Section of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands. 7. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands e.g.e.de.vries@umcg.nl.
Abstract
UNLABELLED: AMG 110, a bispecific T cell engager (BiTE) antibody construct, induces T cell-mediated cancer cell death by cross-linking epithelial cell adhesion molecule (EpCAM) on tumor cells with a cluster of differentiation 3 ε (CD3ε) on T cells. We labeled AMG 110 with (89)Zr or near-infrared fluorescent dye (IRDye) 800CW to study its tumor targeting and tissue distribution. METHODS: Biodistribution and tumor uptake of (89)Zr-AMG 110 was studied up to 6 d after intravenous administration to nude BALB/c mice bearing high EpCAM-expressing HT-29 colorectal cancer xenografts. Tumor uptake of (89)Zr-AMG 110 was compared with uptake in head and neck squamous cell cancer FaDu (intermediate EpCAM) and promyelocytic leukemia HL60 (EpCAM-negative) xenografts. Intratumoral distribution in HT-29 tumors was studied using 800CW-AMG 110. RESULTS: Tumor uptake of (89)Zr-AMG 110 can be clearly visualized using small-animal PET imaging up to 72 h after injection. The highest tumor uptake of (89)Zr-AMG 110 at the 40-μg dose level was observed at 6 and 24 h (respectively, 5.35 ± 0.22 and 5.30 ± 0.20 percentage injected dose per gram; n = 3 and 4). Tumor uptake of (89)Zr-AMG 110 was EpCAM-specific and correlated with EpCAM expression. 800CW-AMG 110 accumulated at the tumor cell surface in viable EpCAM-expressing tumor tissue. CONCLUSION: PET and fluorescent imaging provided real-time information about AMG 110 distribution and tumor uptake in vivo. Our data support using (89)Zr and IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical and clinical settings.
UNLABELLED: AMG 110, a bispecific T cell engager (BiTE) antibody construct, induces T cell-mediated cancer cell death by cross-linking epithelial cell adhesion molecule (EpCAM) on tumor cells with a cluster of differentiation 3 ε (CD3ε) on T cells. We labeled AMG 110 with (89)Zr or near-infrared fluorescent dye (IRDye) 800CW to study its tumor targeting and tissue distribution. METHODS: Biodistribution and tumor uptake of (89)Zr-AMG 110 was studied up to 6 d after intravenous administration to nude BALB/c mice bearing high EpCAM-expressing HT-29 colorectal cancer xenografts. Tumor uptake of (89)Zr-AMG 110 was compared with uptake in head and neck squamous cell cancer FaDu (intermediate EpCAM) and promyelocytic leukemia HL60 (EpCAM-negative) xenografts. Intratumoral distribution in HT-29 tumors was studied using 800CW-AMG 110. RESULTS:Tumor uptake of (89)Zr-AMG 110 can be clearly visualized using small-animal PET imaging up to 72 h after injection. The highest tumor uptake of (89)Zr-AMG 110 at the 40-μg dose level was observed at 6 and 24 h (respectively, 5.35 ± 0.22 and 5.30 ± 0.20 percentage injected dose per gram; n = 3 and 4). Tumor uptake of (89)Zr-AMG 110 was EpCAM-specific and correlated with EpCAM expression. 800CW-AMG 110 accumulated at the tumor cell surface in viable EpCAM-expressing tumor tissue. CONCLUSION: PET and fluorescent imaging provided real-time information about AMG 110 distribution and tumor uptake in vivo. Our data support using (89)Zr and IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical and clinical settings.
Authors: Anthony F Shields; Paula M Jacobs; Mario Sznol; Michael M Graham; Ron N Germain; Lawrence G Lum; Elizabeth M Jaffee; Elisabeth G E de Vries; Sridhar Nimmagadda; Annick D Van den Abbeele; David K Leung; Anna M Wu; Elad Sharon; Lalitha K Shankar Journal: J Nucl Med Date: 2017-08-17 Impact factor: 10.057
Authors: Stijn J H Waaijer; Frank J Warnders; Sabine Stienen; Matthias Friedrich; Alexander Sternjak; H Kam Cheung; Anton G T Terwisscha van Scheltinga; Carolien P Schröder; Elisabeth G E de Vries; Marjolijn N Lub-de Hooge Journal: Clin Cancer Res Date: 2018-07-06 Impact factor: 12.531
Authors: Frans V Suurs; Grit Lorenczewski; Julie M Bailis; Sabine Stienen; Matthias Friedrich; Fei Lee; Bert van der Vegt; Elisabeth G E de Vries; Derk-Jan A de Groot; Marjolijn N Lub-de Hooge Journal: J Nucl Med Date: 2021-04-30 Impact factor: 11.082
Authors: Brooke N McKnight; Akhila N W Kuda-Wedagedara; Kuntal K Sevak; Dalya Abdel-Atti; Wendy N Wiesend; Anson Ku; Dakshnamurthy Selvakumar; Sean D Carlin; Jason S Lewis; Nerissa T Viola-Villegas Journal: Sci Rep Date: 2018-06-13 Impact factor: 4.379